Fulcrum Therapeutics (FULC) Return on Equity (2020 - 2025)
Historic Return on Equity for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to 0.26%.
- Fulcrum Therapeutics' Return on Equity fell 1900.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year decrease of 1900.0%. This contributed to the annual value of 0.04% for FY2024, which is 4100.0% up from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Return on Equity is 0.26%, which was down 1900.0% from 0.25% recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Return on Equity registered a high of 0.07% during Q1 2025, and its lowest value of 0.62% during Q1 2021.
- For the 5-year period, Fulcrum Therapeutics' Return on Equity averaged around 0.36%, with its median value being 0.4% (2023).
- Per our database at Business Quant, Fulcrum Therapeutics' Return on Equity tumbled by -3900bps in 2021 and then skyrocketed by 5200bps in 2025.
- Fulcrum Therapeutics' Return on Equity (Quarter) stood at 0.37% in 2021, then plummeted by -43bps to 0.52% in 2022, then rose by 24bps to 0.4% in 2023, then skyrocketed by 90bps to 0.04% in 2024, then tumbled by -566bps to 0.26% in 2025.
- Its Return on Equity was 0.26% in Q3 2025, compared to 0.25% in Q2 2025 and 0.07% in Q1 2025.